ALDH1A2
ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.
Overview
Catalyses the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively. Retinoate signalling is critical for the transcriptional control of many genes, for instance it is crucial for initiation of meiosis in both male and female. Recognises retinal as substrate, both in its free form and when bound to cellular retinol-binding protein.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Tretinoin.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.
- 1 · What it is
ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.
- 2 · What goes wrong in cancer
Catalyses the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively.
- 3 · How drugs use it
No product in this corpus aims at ALDH1A2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:15472 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O94788 (protein name, function text, keywords and locations (REST API)); CIViC gene ALDH1A2 (3 evidence items, 0 assertions, 2 variants; diseases: Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0))
Biology
Catalyses the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively. Retinoate signalling is critical for the transcriptional control of many genes, for instance it is crucial for initiation of meiosis in both male and female. Recognises retinal as substrate, both in its free form and when bound to cellular retinol-binding protein. Can metabolise octanal and decanal, but has only very low activity with benzaldehyde, acetaldehyde and propanal. Displays complete lack of activity with citral. Location: Cytoplasm (UniProt). Locus 15q21.3 (HGNC).
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ALDH1A2" OR ABSTRACT:"ALDH1A2" OR TITLE:"aldehyde dehydrogenase 1 family member A2" OR ABSTRACT:"aldehyde dehydrogenase 1 family member A2" OR TITLE:"Retinal dehydrogenase 2" OR ABSTRACT:"Retinal dehydrogenase 2" OR TITLE:"RALDH2" OR ABSTRACT:"RALDH2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ALDH1A2, not a curated reading list.